Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
0.72x
NATCOPHARM's operating cash flow covered 72% of net income in FY 2024. Some earnings may be tied up in working capital.
Free Cash Flow
₹8.72B
NATCOPHARM's free cash flow was ₹8.72B in FY 2024, up 24.1% from FY 2023.
Dividend Coverage
5.1x
NATCOPHARM's free cash flow covered dividends 5.1x in FY 2024, leaving room for reinvestment or debt reduction.
CapEx Intensity
28.0%
Capital expenditure was 28.0% of operating cash flow in FY 2024 for NATCOPHARM, indicating a capital-light business.
Hover the chart icon for YoY change.
| Item | Chart | 2023 | 2024 |
|---|---|---|---|
| Net Income | 8.62B | 16.74B | |
| Cash flow Operating Activities | 8.49B | 12.12B | |
| Investments in PPE | -1.46B | -3.39B | |
| Cash flow Investing Activities | -4.77B | -10.33B | |
| Dividend Paid | -1.00B | -1.71B | |
| Cash flow Financing Activities | -3.63B | -2.47B | |
| Cash at beginning of period | 1.11B | 1.32B | |
| Cash at end of period | 1.32B | 704.00M | |
| Free Cash Flow | 7.03B | 8.72B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2024